Literature DB >> 66477

Intrathymic pathogenesis and dual genetic control of myasthenia gravis.

H Wekerle, U P Ketelsen.   

Abstract

We propose a two-step model for the pathogenesis of myasthenia gravis. In the first step, primitive intrathymic stem-cells are induced by abnormal stimuli to differentiate to (abnormal?) myogenic cells. In the second step, immunocompetent T lymphocytes start an autoimmune reaction against these newly differentiated myogenic cells. The clinical stage is reached when autosensitised effector T lymphocytes leave the thymus and either infiltrate the synaptic spaces of peripheral muscles or participate in the formation of autoantibodies, causing the neuromuscular symptoms. At two points the pathogenesis is under genetic control--the first at the differentiation of the stem-cells to myogenic cells and the second at the immune responsiveness of the lymphocytes to these atypical intrathymic muscle cells.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66477     DOI: 10.1016/s0140-6736(77)92118-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

3.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

4.  Surgical treatment of myasthenia gravis and evaluation of its efficacy.

Authors:  T C Pan; Q F Chen; L H Zhang; Y Z Shen; Z P Xie; M S Yang; B T Bu; X B Cao
Journal:  J Tongji Med Univ       Date:  1991

5.  The thymus in seronegative myasthenia gravis patients.

Authors:  N Willcox; M Schluep; M A Ritter; J Newsom-Davis
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

6.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

7.  Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients.

Authors:  A Melms; B C Schalke; T Kirchner; H K Müller-Hermelink; E Albert; H Wekerle
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

8.  Malignant thymoma with direct invasion into the peritoneal cavity: report of a case.

Authors:  T Fujikawa; Y Nakamura; S Matsusue; H Takeda; Y Kori; M Sonobe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

9.  Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis.

Authors:  A Melms; G Malcherek; U Gern; N Sommer; R Weissert; H Wiethölter; H J Bühring
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

10.  The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.

Authors:  E Meinl; W E Klinkert; H Wekerle
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.